Melanoma-associated antigen 1 (MAGE-A1) peptide-MHC complex (MAGE-A1/MHC)

The MHC class I/II molecules presenting MAGE-1-derived peptides are critical targets in cancer immunotherapy, representing the first identified human tumor-associated antigens recognized by T cells (Source: van der Bruggen et al., Science, 1991, PMID: 1840665). MAGE-A1 (Melanoma-associated antigen 1) is a member of the cancer-testis antigen family, which is characterized by expression in various malignancies but restricted expression in normal tissues, primarily the immune-privileged testis and placenta (Source: UniProt P43355). In tumor cells, MAGE-A1 is degraded by the proteasome into peptides, such as the HLA-A1-restricted nonamer EADPTGHSY, which are then transported to the cell surface by MHC Class I or II molecules (Source: Trautmann et al., J Immunol, 2002). These complexes serve as ligands for specific T-cell receptors (TCRs) on CD8+ and CD4+ T cells, respectively, triggering an immune response against the cancer cell. Therapeutic interventions targeting this complex include peptide vaccines, TCR-engineered T-cell (TCR-T) therapies, and TCR-like antibodies designed to mimic T-cell recognition (Source: Dutoit et al., Cancer Res, 2001). Because of the high tumor specificity of MAGE-A1, these targets are highly valued for minimizing off-tumor toxicity, although potential cross-reactivity with similar peptides in healthy tissues remains a significant safety consideration (Source: Linette et al., Blood, 2013).

Other names

MAGE-1/HLA complexMAGE-A1/HLA-A1 complexMAGE-A1/HLA-A*01:01Antigen MZ2-ECancer/testis antigen 1.1MAGE-A1/HLA-DP4 complex

Targeting of tumor cells via T-cell receptor (TCR) recognition of the specific peptide-MHC complex, leading to cytotoxic T-lymphocyte (CTL) mediated lysis and cytokine production.